Posted by Michael Wonder on 02 Sep 2022
First de novo deuterated drug poised for approval
1 September 2022 - Bristol Myers Squibb’s first in class TYK2 inhibitor and blockbuster contender deucravacitinib showcases the role for heavy hydrogen in novel drug discovery.
One of the smallest changes a medicinal chemist can make to a compound is to swap a hydrogen atom for its isotope deuterium. But this tiny tweak can have an outsized effect.
